Clinical and Experimental Reproductive Medicine

  • 제48권1호
  • /
  • Pages.1-10
  • /
  • 2021
  • /
  • 2233-8233(pISSN)
  • /
  • 2233-8241(eISSN)
대한생식의학회 (The Korean Society for Reproductive Medicine)
권호 표지
DOI QR코드

DOI QR Code

Controlled ovarian hyperstimulation for fertility preservation in women with breast cancer: Practical issues

  • Park, So Yun (Department of Obstetrics and Gynecology, Ewha Womans University College of Medicine) ;
  • Jeong, Kyungah (Department of Obstetrics and Gynecology, Ewha Womans University College of Medicine) ;
  • Cho, Eun Hye (Department of Obstetrics and Gynecology, Ewha Womans University College of Medicine) ;
  • Chung, Hye Won (Department of Obstetrics and Gynecology, Ewha Womans University College of Medicine)
  • 투고 : 2020.02.18
  • 심사 : 2020.08.12
  • 발행 : 2021.03.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

In Korean women, a westernized lifestyle is associated with an increased risk of breast cancer. Fertility preservation has become an increasingly important issue for women with breast cancer, in accordance with substantial improvements in survival rate after cancer treatment. The methods of controlled ovarian hyperstimulation (COH) for fertility preservation in breast cancer patients have been modified to include aromatase inhibitors to reduce the potential harm associated with increased estradiol levels. Random-start COH and dual ovarian stimulation are feasible options to reduce the total duration of fertility preservation treatment and to efficiently collect oocytes or embryos. Using a gonadotropin-releasing hormone agonist as a trigger may improve cycle outcomes in breast cancer patients undergoing COH for fertility preservation. In young breast cancer patients with BRCA mutations, especially BRCA1 mutations, the possibility of diminished ovarian reserve may be considered, although further studies are necessary. Herein, we review the current literature on the practical issues surrounding COH for fertility preservation in women with breast cancer.

키워드

참고문헌

  1. World Health Organization. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 [Internet]. Lyon: World Health Organization International Agency for Research on Cancer; 2012 [cited 2020 Oct 29]. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
  2. Ruddy KJ, Gelber SI, Tamimi RM, Ginsburg ES, Schapira L, Come SE, et al. Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol 2014;32:1151-6. https://doi.org/10.1200/JCO.2013.52.8877
  3. Ganz PA, Bower JE, Stanton AL. Special issues in younger women with breast cancer. Adv Exp Med Biol 2015;862:9-21. https://doi.org/10.1007/978-3-319-16366-6_2
  4. National Cancer Institute. SEER cancer statistics review (CSR) 1975-2012: cancer of the female breast (invasive) [Internet]. Bethesda: National Cancer Institute; 2015 [cited 2020 Oct 29]. Available from: http://seer.cancer.gov/csr/1975_2012/browse_csr.php?sectionSEL=4&pageSEL=sect_04_table.14.html.
  5. Ko BS, Noh WC, Kang SS, Park BW, Kang EY, Paik NS, et al. Changing patterns in the clinical characteristics of Korean breast cancer from 1996-2010 using an online nationwide breast cancer data-base. J Breast Cancer 2012;15:393-400. https://doi.org/10.4048/jbc.2012.15.4.393
  6. Kim H, Kim SK, Lee JR, Hwang KJ, Suh CS, Kim SH. Fertility preservation for patients with breast cancer: The Korean Society for Fertility Preservation clinical guidelines. Clin Exp Reprod Med 2017; 44:181-6. https://doi.org/10.5653/cerm.2017.44.4.181
  7. Advani P, Moreno-Aspitia A. Current strategies for the prevention of breast cancer. Breast Cancer (Dove Med Press) 2014;6:59-71. https://doi.org/10.1007/BF02966908
  8. Zhou W, Slingerland JM. Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy. Nat Rev Cancer 2014;14:26-38. https://doi.org/10.1038/nrc3622
  9. Nilsson S, Gustafsson JA. Estrogen receptor action. Crit Rev Eukaryot Gene Expr 2002;12:237-57. https://doi.org/10.1615/CritRevEukaryotGeneExpr.v12.i4.10
  10. Huang C, Wang X, Sun B, Li M, Zhao X, Gu Y, et al. Study on mouse model of triple-negative breast cancer: association between higher parity and triple-negative breast cancer. Target Oncol 2015;10:85-97. https://doi.org/10.1007/s11523-014-0316-y
  11. Palmer JR, Boggs DA, Wise LA, Ambrosone CB, Adams-Campbell LL, Rosenberg L. Parity and lactation in relation to estrogen receptor negative breast cancer in African American women. Cancer Epidemiol Biomarkers Prev 2011;20:1883-91. https://doi.org/10.1158/1055-9965.EPI-11-0465
  12. Shim YJ, Seol A, Lee D, Kim SK, Lee JR, Jee BC, et al. The serum estradiol/oocyte ratio in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins. Obstet Gynecol Sci 2018;61:242-6. https://doi.org/10.5468/ogs.2018.61.2.242
  13. Turan V, Bedoschi G, Emirdar V, Moy F, Oktay K. Ovarian stimulation in patients with cancer: impact of letrozole and BRCA mutations on fertility preservation cycle outcomes. Reprod Sci 2018; 25:26-32. https://doi.org/10.1177/1933719117728800
  14. Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 2005;23:4347-53. https://doi.org/10.1200/JCO.2005.05.037
  15. Oktay K, Buyuk E, Rodriguez-Wallberg KA, Sahin G. In vitro maturation improves oocyte or embryo cryopreservation outcome in breast cancer patients undergoing ovarian stimulation for fertility preservation. Reprod Biomed Online 2010;20:634-8. https://doi.org/10.1016/j.rbmo.2010.01.012
  16. Oktay K, Hourvitz A, Sahin G, Oktem O, Safro B, Cil A, et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab 2006;91:3885-90. https://doi.org/10.1210/jc.2006-0962
  17. Domingo J, Guillen V, Ayllon Y, Martinez M, Munoz E, Pellicer A, et al. Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment. Fertil Steril 2012;97:930-4. https://doi.org/10.1016/j.fertnstert.2012.01.093
  18. Revelli A, Porcu E, Levi Setti PE, Delle Piane L, Merlo DF, Anserini P. Is letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer? Gynecol Endocrinol 2013;29:993-6. https://doi.org/10.3109/09513590.2013.819083
  19. Azim AA, Costantini-Ferrando M, Lostritto K, Oktay K. Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metab 2007;92:2197-200. https://doi.org/10.1210/jc.2007-0247
  20. Checa Vizcaino MA, Corchado AR, Cuadri ME, Comadran MG, Brassesco M, Carreras R. The effects of letrozole on ovarian stimulation for fertility preservation in cancer-affected women. Reprod Biomed Online 2012;24:606-10. https://doi.org/10.1016/j.rbmo.2012.02.020
  21. Domingo J, Garcia-Velasco JA. Oocyte cryopreservation for fertility preservation in women with cancer. Curr Opin Endocrinol Diabetes Obes 2016;23:465-9. https://doi.org/10.1097/MED.0000000000000295
  22. Rodgers RJ, Reid GD, Koch J, Deans R, Ledger WL, Friedlander M, et al. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review. Hum Reprod 2017;32:1033-45. https://doi.org/10.1093/humrep/dex027
  23. Kim J, Turan V, Oktay K. Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer. J Clin Endocrinol Metab 2016;101:1364-71. https://doi.org/10.1210/jc.2015-3878
  24. Meirow D, Raanani H, Maman E, Paluch-Shimon S, Shapira M, Cohen Y, et al. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies. Fertil Steril 2014;102:488-95. https://doi.org/10.1016/j.fertnstert.2014.05.017
  25. Cakmak H, Rosen MP. Random-start ovarian stimulation in patients with cancer. Curr Opin Obstet Gynecol 2015;27:215-21. https://doi.org/10.1097/GCO.0000000000000180
  26. Cakmak H, Tran ND, Zamah AM, Cedars MI, Rosen MP. A novel "delayed start" protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders. Fertil Steril 2014;101:1308-14. https://doi.org/10.1016/j.fertnstert.2014.01.050
  27. Cakmak H, Katz A, Cedars MI, Rosen MP. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril 2013;100:1673-80. https://doi.org/10.1016/j.fertnstert.2013.07.1992
  28. Martinez F, Clua E, Devesa M, Rodriguez I, Arroyo G, Gonzalez C, et al. Comparison of starting ovarian stimulation on day 2 versus day 15 of the menstrual cycle in the same oocyte donor and pregnancy rates among the corresponding recipients of vitrified oocytes. Fertil Steril 2014;102:1307-11. https://doi.org/10.1016/j.fertnstert.2014.07.741
  29. Danis RB, Pereira N, Elias RT. Random start ovarian stimulation for oocyte or embryo cryopreservation in women desiring fertility preservation prior to gonadotoxic cancer therapy. Curr Pharm Biotechnol 2017;18:609-13.
  30. Kuang Y, Chen Q, Hong Q, Lyu Q, Ai A, Fu Y, et al. Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol). Reprod Biomed Online 2014;29:684-91. https://doi.org/10.1016/j.rbmo.2014.08.009
  31. Ubaldi FM, Capalbo A, Vaiarelli A, Cimadomo D, Colamaria S, Alviggi C, et al. Follicular versus luteal phase ovarian stimulation during the same menstrual cycle (DuoStim) in a reduced ovarian reserve population results in a similar euploid blastocyst formation rate: new insight in ovarian reserve exploitation. Fertil Steril 2016;105:1488-95. https://doi.org/10.1016/j.fertnstert.2016.03.002
  32. Moffat R, Pirtea P, Gayet V, Wolf JP, Chapron C, de Ziegler D. Dual ovarian stimulation is a new viable option for enhancing the oocyte yield when the time for assisted reproductive technnology is limited. Reprod Biomed Online 2014;29:659-61. https://doi.org/10.1016/j.rbmo.2014.08.010
  33. Cardoso MC, Evangelista A, Sartorio C, Vaz G, Werneck CL, Guimaraes FM, et al. Can ovarian double-stimulation in the same menstrual cycle improve IVF outcomes? JBRA Assist Reprod 2017;21:217-21.
  34. Liu C, Jiang H, Zhang W, Yin H. Double ovarian stimulation during the follicular and luteal phase in women ≥ 38 years: a retrospective case-control study. Reprod Biomed Online 2017;35:678-84. https://doi.org/10.1016/j.rbmo.2017.08.019
  35. Vaiarelli A, Venturella R, Vizziello D, Bulletti F, Ubaldi FM. Dual ovarian stimulation and random start in assisted reproductive technologies: from ovarian biology to clinical application. Curr Opin Obstet Gynecol 2017;29:153-9. https://doi.org/10.1097/GCO.0000000000000365
  36. Nakasuji T, Kawai K, Ishikawa T, Teraoka K, Takeuchi S, Miyagawa T, et al. Random-start ovarian stimulation with aromatase inhibitor for fertility preservation in women with Japanese breast cancer. Reprod Med Biol 2019;18:167-72. https://doi.org/10.1002/rmb2.12263
  37. Reddy J, Turan V, Bedoschi G, Moy F, Oktay K. Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience. J Assist Reprod Genet 2014;31:927-32. https://doi.org/10.1007/s10815-014-0248-6
  38. Yilmaz N, Ceran MU, Ugurlu EN, Gulerman HC, Engin Ustun Y. GnRH agonist versus HCG triggering in different IVF/ICSI cycles of same patients: a retrospective study. J Obstet Gynaecol 2020;40: 837-42. https://doi.org/10.1080/01443615.2019.1674262
  39. Lin MH, Wu FS, Hwu YM, Lee RK, Li RS, Li SH. Dual trigger with gonadotropin releasing hormone agonist and human chorionic gonadotropin significantly improves live birth rate for women with diminished ovarian reserve. Reprod Biol Endocrinol 2019;17:7. https://doi.org/10.1186/s12958-018-0451-x
  40. Goldrat O, Van Den Steen G, Gonzalez-Merino E, Dechene J, Gervy C, Delbaere A, et al. Letrozole-associated controlled ovarian hyperstimulation in breast cancer patients versus conventional controlled ovarian hyperstimulation in infertile patients: assessment of oocyte quality related biomarkers. Reprod Biol Endocrinol 2019;17:3. https://doi.org/10.1186/s12958-018-0443-x
  41. Asada Y, Itoi F, Honnma H, Takiguchi S, Fukunaga N, Hashiba Y, et al. Failure of GnRH agonist-triggered oocyte maturation: its cause and management. J Assist Reprod Genet 2013;30:581-5. https://doi.org/10.1007/s10815-013-9966-4
  42. Chen CH, Tzeng CR, Wang PH, Liu WM, Chang HY, Chen HH, et al. Dual triggering with GnRH agonist plus hCG versus triggering with hCG alone for IVF/ICSI outcome in GnRH antagonist cycles: a systematic review and meta-analysis. Arch Gynecol Obstet 2018; 298:17-26. https://doi.org/10.1007/s00404-018-4751-3
  43. Titus S, Li F, Stobezki R, Akula K, Unsal E, Jeong K, et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med 2013;5:172ra21. https://doi.org/10.1126/scitranslmed.3004925
  44. Peccatori FA, Mangili G, Bergamini A, Filippi F, Martinelli F, Ferrari F, et al. Fertility preservation in women harboring deleterious BRCA mutations: ready for prime time? Hum Reprod 2018;33:181-7. https://doi.org/10.1093/humrep/dex356
  45. Gunnala V, Fields J, Irani M, D'Angelo D, Xu K, Schattman G, et al. BRCA carriers have similar reproductive potential at baseline to noncarriers: comparisons in cancer and cancer-free cohorts undergoing fertility preservation. Fertil Steril 2019;111:363-71. https://doi.org/10.1016/j.fertnstert.2018.10.014
  46. Son KA, Lee DY, Choi D. Association of BRCA mutations and anti-Mullerian hormone level in young breast cancer patients. Front Endocrinol (Lausanne) 2019;10:235. https://doi.org/10.3389/fendo.2019.00235
  47. Winship AL, Willson C, Hansen KR, Hutt KJ, Hickey M. Do BRCA1 and BRCA2 gene mutation carriers have a reduced ovarian reserve? Protocol for a prospective observational study. BMJ Open 2019;9:e033810. https://doi.org/10.1136/bmjopen-2019-033810
  48. Porcu E, Cillo GM, Cipriani L, Sacilotto F, Notarangelo L, Damiano G, et al. Impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes in young women with breast cancer. J Assist Reprod Genet 2020;37:709-15. https://doi.org/10.1007/s10815-019-01658-9